Hematopoietic stem cell transplantation for Morquio A syndrome

Molecular Genetics and Metabolism

Volumn 117, Issue 2, 2016, Pages 84-94

  Yabe, Hiromasa ^a   Tanaka, Akemi ^b   Chinen, Yasutsugu ^c   Kato, Shunichi ^a   Sawamoto, Kazuki ^e   Yasuda, Eriko ^e   Shintaku, Haruo ^b   Suzuki, Yasuyuki ^d   Orii, Tadao ^d   Tomatsu, Shunji ^d,e  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d GIFU UNIVERSITY   (Japan)

^e NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

ADL; GVHD; Hematopoietic stem cell transplantation; Morquio A syndrome; Respiratory function

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; PREDNISOLONE; THYMOCYTE ANTIBODY; URONIC ACID;

ADENOIDECTOMY; ADULT; ANKLE FOOT ORTHOSIS; ARTHRALGIA; ARTICLE; BONE DENSITY; CASE REPORT; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPNEA; ECHOCARDIOGRAPHY; ENGRAFTMENT; ENZYME ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; GRAFT VERSUS HOST REACTION; HEARING IMPAIRMENT; HEART FUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HLA TYPING; HUMAN; HYPOPLASIA; IMMUNOSUPPRESSIVE TREATMENT; KYPHOSCOLIOSIS; KYPHOSIS; LEUKOCYTE; MALE; MORQUIO SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; ODONTOID HYPOPLASIA; OSTEOTOMY; PEAK EXPIRATORY FLOW; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; RANGE OF MOTION; SHORT COURSE THERAPY; SHORT STATURE; SNORING; SPINAL CORD COMPRESSION; TONSILLECTOMY; VALGUS DEFORMITY; VALGUS KNEE; WALKING DIFFICULTY; X RAY PICTURE; BODY HEIGHT; BONE MARROW TRANSPLANTATION; DIAGNOSTIC IMAGING; MUCOPOLYSACCHARIDOSIS IV; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; BODY HEIGHT; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MUCOPOLYSACCHARIDOSIS IV; TREATMENT OUTCOME;

EID: 84957894749     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2015.09.011     Document Type: Article

References (46)

1. Dorfman A., Arbogast B., Matalon R. The enzymic defects in Morquio and Maroteaux-Lamy syndrome. Adv. Exp. Med. Biol. 1976, 68:261-276.
2. Montaño A.M., Tomatsu S., Gottesman G.S., Smith M., Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J. Inherit. Metab. Dis. 2007, 30:165-174.
3. Montaño A.M., Tomatsu S., Brusius A., Smith M., Orii T. Growth charts for patients affected with Morquio A disease. Am. J. Med. Genet. A. 2008, 146:1286-1295.
4. Tomatsu S., Montaño A.M., Oikawa H., et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Cur. Pharm. Biotech. 2011, 12:931-945.
5. Tomatsu S., Mackenzie W.G., Theroux M.C., et al. Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Res. Rep. Endocr. Disord. 2012, 2:65-77.
6. S. Tomatsu, A.M. Montaño, H. Oikawa et al., Impairment of body growth in mucopolysaccharidoses. 2091-2116. In: V.R. Preedy (Ed.), Handbook of Growth and Growth Monitoring in Health and Disease, DOI 10.1007/978-1-4419-1795-9_126, © Springer science + Business media, LLC 2012b.
7. Hendriksz C.J., Harmatz P., Beck M., et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol. Genet. Metab. 2013, 110:54-64.
8. Ohashi A., Montaño A.M., Colón J.E., Oguma T., Luisiri A., Tomatsu S. Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease. Acta. Paediatr. 2009, 98:768-769. (910-912).
9. Theroux M.C., Nerker T., Ditro C., Mackenzie W.G. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr. Anaesth. 2012, 22:901-907.
10. C. Lavery, C. Hendriksz, Mortality in patients with Morquio syndrome A, JIMD. Rep. 15 (2015) 59-66.
11. Tomatsu S., Sawamoto K., Alméciga-Díaz C.J., et al. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. Drug. Des. Devel. Ther. 2015, 9:1937-1953. Apr 1. doi: 10.2147/DDDT.S68562. eCollection 2015. Review.
12. Tomatsu S., Alméciga-Díaz C.J., Montaño A.M., et al. Therapies for the bone in mucopolysaccharidoses. Mol. Genet. Metab. 2015, 114:94-109.
13. Chinen Y., Higa T., Tomatsu S., Suzuki Y., Orii T., Hyakuna N. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol. Genet. Metab. Rep. 2014, 1:31-41.
14. Tomatsu S., Yasuda E., Patel P., et al. Morquio A syndrome: diagnosis and current and future therapies. Pediatr. Endocrinol. Rev. 2014, 12(suppl 1):141-151.
15. Connock M., Juarez-Garcia A., Frew E., et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type I. Health Technol. Assess. 2006, 10:iii-iiv. ix-113.
16. Rohrbach M., Clarke J.T. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007, 67:2697-2716.
17. Hobbs J.R., Hugh-Jones K., Byrom N., et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone marrow transplantation. Lancet 1981, 2:709-712.
18. Hobbs J.R. Correction of 34 genetic diseases by displacement bone marrow transplantation. Plasma Ther. Transfus. Technol. 1985, 6:221-246.
19. Hoogerbrugge P.M., Brouwer O.F., Bordigoni P., et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995, 345:1398-1402.
20. Yasuda E., Mackenzie W.G., Ruhnke K., et al. Long-term follow-up of post haematopoietic stem cell transplantation for the patient with Hurler syndrome: correlation between pathological phenotype, biomarker and clinical improvement. Mol. Genet. Metab. Rep. 2015, 2:65-76.
21. Tanjuakio J., Suzuki Y., Patel P., et al. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Mol. Genet. Metab. 2015, 114:161-169.
22. Patel P., Suzuki Y., Tanaka A., et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome. Mol. Genet. Metab. Rep. 2014, 1:184-196.
23. Tanaka A., Okuyama T., Suzuki Y., et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol. Genet. Metab. 2012, 107:513-520.
24. Tomatsu S., Montaño A.M., Nishioka T., et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum. Mutat. 2005, 26:500-512.
25. Tomatsu S., Montaño A.M., Lopez P., et al. Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA gene. Mol. Genet. Metab. 2006, 89:139-149.
26. Yabe H., Yabe M., Hattori K., et al. Preconditioning regimens for bone marrow transplantation in patients with congenital metabolic diseases. Exp. Hematol. 2001, 29(suppl):94.
27. Japan Society for Hematopoietic Cell Transplantation Monograph 2002, 7:39.
28. Aldenhoven M., Jones S.A., Bonney D., Borrill R.E., Coussons M., Mercer J., Bierings M.B., Versluys B., van Hasselt P.M., Wijburg F.A., van der Ploeg A.T., Wynn R.F., Boelens J.J. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. See comment in PubMed Commons below. Biol. Blood Marrow Transplant 2015, 21:1106-1109.
29. Bernardo M.E., Piras E., Vacca A., et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012, 120:473-476.
30. Slatter M.A., Rao K., Amrolia P., et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011, 117:4367-4375.
31. Strocchio L., Zecca M., Comoli P., et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br. J. Haematol. 2015, 169:726-736.
32. Wachowiak J., Sykora K.W., Cornish J., et al. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 2011, 46:1510-1518.
33. Schwinger W., Sovinz P., Benesch M., et al. Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome. Pediatr. Hematol. Oncol. 2014, 31:723-730.
34. Tomatsu S., Fujii T., Fukushi M., et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol. Genet. Metab. 2013, 110:42-53.
35. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic Basis of Inherited Diseases 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
36. Peters C., Shapiro E.G., Anderson J., et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998, 91:2601-2608.
37. Staba S.L., Escolar M.L., Poe M., et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N. Engl. J. Med. 2004, 350:1960-1969.
38. Guffon N., Bertrand Y., Forest I., Fouilhoux A., Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J. Pediatr. 2009, 154:733-737.
39. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin. Immunopathol. 2004, 26:119-132.
40. Yamada Y., Kato K., Sukegawa K., et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 1988, 21:629-634.
41. Orchard P.J., Blazar B.R., Wagner J., Charnas L., Krivit W., Tolar J. Hematopoietic cell therapy for metabolic disease. J. Pediatr. 2007, 151:340-346.
42. S. Belinson, B. Mauger Rothenberg, R. Chopra, N. Aronson, Future research needs for hematopoietic stem-cell transplantation in the pediatric population: identification of future research needs from comparative effectiveness review No. 48 [Internet], Rockville (MD): Agency for Healthcare Research and Quality (US), (2012).
43. Tomatsu S., Alméciga-Díaz C.J., Barbosa H., Montaño A.M., et al. Therapies of Mucopolysaccharidosis IVA (Morquio A Syndrome). Expert Opin. Orphan Drugs 2013, 1:805-818.
44. Boelens J.J., Aldenhoven M., Purtill D., et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013, 121:3981-3987.
45. Tse W., Laughlin M.J. Umbilical cord blood transplantation: a new alternative option. Hematology Am. Soc. Hematol. Educ. Program 2005, 377-383.
46. Tomatsu S., Averill L.W., Sawamoto K., Mackenzie W.G., Bober M.B., Pizarro C., Goff C.J., Xie L., Orii T., Theroux M. Obstructive airway in Morquio A syndrome, the past, the present and the future. Mol. Genet. Metab. 2016, 117:150-156.